Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel
Jazyk angličtina Země Spojené státy americké Médium print
Typ dokumentu časopisecké články, přehledy
PubMed
28938795
DOI
10.1093/nutrit/nux047
PII: 4065280
Knihovny.cz E-zdroje
- Klíčová slova
- dyslipidemia, lipid, nutraceuticals, position paper, recommendations,
- MeSH
- dyslipidemie krev farmakoterapie epidemiologie MeSH
- fytonutrienty aplikace a dávkování krev farmakokinetika MeSH
- HDL-cholesterol krev MeSH
- intestinální absorpce účinky léků MeSH
- játra účinky léků metabolismus MeSH
- kardiovaskulární nemoci krev farmakoterapie epidemiologie MeSH
- LDL-cholesterol krev MeSH
- lékové interakce MeSH
- lidé MeSH
- medicína založená na důkazech MeSH
- metaanalýza jako téma MeSH
- nenasycené mastné kyseliny aplikace a dávkování krev farmakokinetika MeSH
- potravní doplňky * MeSH
- pozorovací studie jako téma MeSH
- probiotika aplikace a dávkování farmakokinetika MeSH
- randomizované kontrolované studie jako téma MeSH
- rizikové faktory MeSH
- statiny terapeutické užití MeSH
- triglyceridy krev MeSH
- životní styl MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
- Názvy látek
- fytonutrienty MeSH
- HDL-cholesterol MeSH
- LDL-cholesterol MeSH
- nenasycené mastné kyseliny MeSH
- statiny MeSH
- triglyceridy MeSH
In recent years, there has been growing interest in the possible use of nutraceuticals to improve and optimize dyslipidemia control and therapy. Based on the data from available studies, nutraceuticals might help patients obtain theraputic lipid goals and reduce cardiovascular residual risk. Some nutraceuticals have essential lipid-lowering properties confirmed in studies; some might also have possible positive effects on nonlipid cardiovascular risk factors and have been shown to improve early markers of vascular health such as endothelial function and pulse wave velocity. However, the clinical evidence supporting the use of a single lipid-lowering nutraceutical or a combination of them is largely variable and, for many of the nutraceuticals, the evidence is very limited and, therefore, often debatable. The purpose of this position paper is to provide consensus-based recommendations for the optimal use of lipid-lowering nutraceuticals to manage dyslipidemia in patients who are still not on statin therapy, patients who are on statin or combination therapy but have not achieved lipid goals, and patients with statin intolerance. This statement is intended for physicians and other healthcare professionals engaged in the diagnosis and management of patients with lipid disorders, especially in the primary care setting.
Biotechnology Research Center Mashhad University of Medical Sciences Mashhad Iran
Department of Primary Care and Public Health Imperial College London UK
Citace poskytuje Crossref.org
